A Preview Of Piedmont Office Realty’s Earnings

Piedmont Office Realty (NYSE:PDM) is set to give its latest quarterly earnings report on Wednesday, 2022-11-02. Here's what investors need to know before the announcement. Analysts estimate that Piedmont Office Realty will report an earnings per share (EPS) of $0.08.

Piedmont Office Realty (NYSE:PDM) is set to give its latest quarterly earnings report on Wednesday, 2022-11-02. Here’s what investors need to know before the announcement.

Analysts estimate that Piedmont Office Realty will report an earnings per share (EPS) of $0.08.

Piedmont Office Realty bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Here’s a look at Piedmont Office Realty’s past performance and the resulting price change:

Quarter Q2 2022 Q1 2022 Q4 2021 Q3 2021
EPS Estimate 0.50 0.49
EPS Actual 0.5 0.51 0.51 0.50
Price Change % 0.75% 2.09% -4.79% 1.8%

Stock Performance

Shares of Piedmont Office Realty were trading at $10.45 as of October 31. Over the last 52-week period, shares are down 43.17%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.

To track all earnings releases for Piedmont Office Realty visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Organigram Reports 16% YoY Revenue Drop But Kicks Off Year ‘With A Bang,’ Says CEO On Hundreds Of Millions In Tobacco Giant BAT Investment

Canadian cannabis producer Organigram reported a 16% decrease in net revenue for Q1 2024 due to a reduction in international revenue and medical sales. The company announced in November that it had received a CA$124.6m ($93m) strategic equity investment from BT DE Investments, a subsidiary of tobacco company British American Tobacco. Organigram shareholders approved the investment in January, and the company completed the first tranche of the investment for $41.5m. CEO Beena Goldenberg said the investment had removed a significant amount of risk from Organigram's business and enhanced its competitive advantages. The investment allows the cannabis producer to utilize its facilities, research and development capabilities, and market leadership to expand its reach within the Canadian market and beyond. Organigram's Q1 financial highlights included a drop in gross margin, an increase in selling and administrative expenses, a net loss of CA$15.8m, and positive adjusted EBITDA of CA$135,000.

BTI